Replies to post #13961 on Momenta Pharmaceuticals, Inc. (MNTA)

[ThSeeker]

If you have a long term view. This could be a big winner. It is well positioned to profit from

...But the FDA approval of the first a whole new kind of generic called a biosimilar earlier this year clears the way for a significant potential market for Momenta. Wheeler said the company has one partnership in place with Baxter International (NYSE: BAX) for a generic of the arthritis drug, Humira, the world’s top-selling drug which is expected to generate $14 billion in revenues for drugmaker AbbVie this year. It is also seeking a partner for other biosimilars in development...

Biosimilars are expected to be huge even more so than transition that occurred when generics were first released. Momenta should be a big player in that transition. Considering the big move it already has seen it could take awhile as some of that may already be priced in.
Marc Lichenfeld, Oxford Club/The Street.com/Oxford Income Letter says that he has identified five companies that will give their investors huge returns on/before October 20, 2015. Momenta is one of them.

[DewDiligence]

After this run, do you see further gains.

The next major market-moving event is pretty likely to be the announcement of a new FoB partner, which MNTA has said will occur by the end of 2015. Whether the announcement makes the share price go up or down depends, of course, on the deal terms and the identity of the partner.